Pancreatic Cancer Research

ResearcherJinan UniversityNo recent work listed

Mao Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6595-8963; OpenAlex author ID A5066981637. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper

Papers 8

  1. Simultaneous Gemcitabine and Percutaneous CT-Guided Irreversible Electroporation for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1155/2022/3523769↗
  2. Irreversible electroporation plus allogenic Vγ9Vδ2 T cells enhances antitumor effect for locally advanced pancreatic cancer patients. Co-author DOI 10.1038/s41392-020-00260-1↗
  3. Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer. Co-author DOI 10.1007/s12026-017-8959-2↗
  4. Circulating Tumor DNA as a Sensitive Marker in Patients Undergoing Irreversible Electroporation for Pancreatic Cancer. Co-author DOI 10.1159/000490874↗
  5. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic c… Co-author DOI 10.1007/s00432-017-2513-4↗
  6. Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cance… Co-author DOI 10.1016/j.imlet.2017.03.018↗
  7. An important discovery on combination of irreversible electroporation and allogeneic natural killer cell immunotherapy for unresectable pancreatic cancer. Co-author DOI 10.18632/oncotarget.21974↗
  8. Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine. Co-author DOI 10.1007/s00432-015-1968-4↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lizhi Niu · 7 shared papers, 2017–2022 · strength 0.66
  2. Jibing Chen · 6 shared papers, 2017–2020 · strength 0.50
  3. Kecheng Xu · 5 shared papers, 2017–2018 · strength 0.39
  4. Mohammed Alnaggar · 4 shared papers, 2017–2020 · strength 0.36
  5. Yangyang Ma · 1 shared paper, 2022 · strength 0.16
  6. Xiaoyan Zhang · 1 shared paper, 2020 · strength 0.11
  7. Yong Jiang · 1 shared paper, 2020 · strength 0.11
  8. Ke-Cheng Xu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.